The Future of Cardiovascular Care [Forbes]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Forbes
After a century of progress that cut deaths from cardiovascular disease in half, momentum has stalled. Heart disease and stroke remain the leading causes of death worldwide, mortality rates are worsening, and costs in the United States alone are projected to triple to $1.8 trillion by 2050. Against this backdrop, healthcare leaders face a defining challenge: whether they can fundamentally reimagine cardiovascular care quickly enough to meet the scale of the problem. That reimagination is already taking shape inside forward-looking health systems. As Warner Thomas, CEO of Sutter Health and $18 billion enterprise of 25 hospitals served by 57,000 award winning culture explains, “The future of heart and vascular care is personalized, proactive and coordinated at scale. Sutter Health's integrated teams are building on a century of heart and vascular clinical excellence with advanced imaging, minimally invasive techniques, clinical trials and AI to detect disease earlier and treat it more
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]FOX Business Network
- Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.MarketBeat
- How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 2/2/26 - Form 4
- 1/20/26 - Form 4
- 1/16/26 - Form 4
- CYTK's page on the SEC website